{"url_path":"/sec/limnw/8-k/2026-06-03/item-8-01","section_key":"item-8-01","section_title":"Item 8.01 Other Events.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-03","source_url":"https://www.sec.gov/Archives/edgar/data/1971387/0001104659-26-070173-index.html","accession_number":"0001104659-26-070173","cik":"0001971387","ticker":"LIMN","issuer_name":"Liminatus Pharma, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1971387/0001104659-26-070173-index.html","primary_entity_key":"0001971387","primary_entity_name":"Liminatus Pharma, Inc."},"word_count":41,"has_tables":true,"body_markdown":"Item 8.01 Other Events.\n\n \n\nOn June 3, 2026, the Company issued a press release\nannouncing the transactions contemplated by the Inducement Letter Agreement. A copy of the press release is attached hereto as Exhibit\n99.1 and is incorporated herein by reference."}